A phase I trial of intrapleural recombinant human interferon ? (rHuIFN?2b) in patients with malignant pleural effusions

1994 ◽  
Vol 120 (3) ◽  
pp. 169-172 ◽  
Author(s):  
A. Bhatia ◽  
T. W. Rice ◽  
D. McLain ◽  
P. Herzog ◽  
G. T. Budd ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Trial ◽  
Human Interferon ◽  
Pleural Effusions ◽  
Malignant Pleural Effusions

A Phase I-II Study of Recombinant Intrapleural Alpha Interferon in Malignant Pleural Effusions

1992 ◽  
Vol 15 (4) ◽  
pp. 328-330 ◽  
Author(s):  
Mark Davis ◽  
Susan Williford ◽  
Hyman B. Muss ◽  
Douglas R. White ◽  
M. Robert Cooper ◽  
...  
Keyword(s):  
Phase I ◽  
Alpha Interferon ◽  
Pleural Effusions ◽  
Malignant Pleural Effusions

scholarly journals A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions

2010 ◽  
Vol 18 (4) ◽  
pp. 852-860 ◽  
Author(s):  
Daniel H Sterman ◽  
Adri Recio ◽  
Andrew R Haas ◽  
Anil Vachani ◽  
Sharyn I Katz ◽  
...  
Keyword(s):  
Gene Transfer ◽  
Phase I ◽  
Phase I Trial ◽  
Pleural Effusions ◽  
Interferon Β

Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer.

1986 ◽  
Vol 4 (3) ◽  
pp. 408-413 ◽  
Author(s):  
E T Creagan ◽  
J S Kovach ◽  
H J Long ◽  
R L Richardson
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Phase I Trial ◽  
Outpatient Setting ◽  
Small Sample ◽  
Human Interferon ◽  
Recombinant Interferon ◽  
Life Threatening ◽  
Cytotoxic Therapies ◽  
Small Sample Sizes

Interferons manifest diverse immunomodulatory and antiproliferative characteristics. Since their spectrum of toxicities includes primarily fatigue and anorexia rather than the myelosuppression concomitant with cytotoxic therapies, it is conceptually appealing to combine both modalities. We conducted a phase I trial among 18 patients using the combination of leukocyte A recombinant interferon (IFN-rA) and BCNU. The intramuscular (IM) IFN-rA dose for the initial 12 patients was 12 X 10(6) U/m2 three times a week for an anticipated duration of 12 weeks. Among these patients, we escalated the monthly intravenous (IV) BCNU dose from 50 mg/m2 to 150 mg/m2. Six subsequent patients received IFN-rA 12 X 10(6) U/m2, days 1 to 3, and BCNU 150 mg IV on day 3 of each monthly cycle. Dose-limiting toxicities from both regimens were fatigue and myelosuppression. We recognize the limitation of small sample sizes. Nevertheless, in the absence of a significant number of life-threatening toxicities, it appears that near maximal doses of BCNU and concomitant IFN-rA can be administered with safety in an outpatient setting.

951 Phase I study of batimastat (BB94) in the treatment of malignant pleural effusions

1995 ◽  
Vol 31 ◽  
pp. S198
Author(s):  
K. O’Byrne ◽  
V. Macaulay ◽  
M. Saunders ◽  
L. Long ◽  
F. Gleeson ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Pleural Effusions ◽  
Malignant Pleural Effusions

86 A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions

Lung Cancer ◽  
1997 ◽  
Vol 18 ◽  
pp. 25
Author(s):  
R.-P. Perng ◽  
M.-F. Wu ◽  
S.-Y. Lin ◽  
Y.-M. Chen ◽  
J.-Y. Lin ◽  
...  
Keyword(s):  
Phase I ◽  
Pharmacokinetic Study ◽  
Pleural Effusions ◽  
Malignant Pleural Effusions

A phase I feasibility and pharmocokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions

1997 ◽  
Vol 8 (6) ◽  
pp. 565-573 ◽  
Author(s):  
Reury-Perng Perng ◽  
Ming-Fang Wu ◽  
Shan-Yang Lin ◽  
Yuh-Min Chen ◽  
Jye-Yee Lin ◽  
...  
Keyword(s):  
Phase I ◽  
Pleural Effusions ◽  
Malignant Pleural Effusions
Sign in / Sign up

Export Citation Format

Share Document